In the last trading session, 1.0 million Kyverna Therapeutics Inc (NASDAQ:KYTX) shares changed hands as the company’s beta touched 1.85. With the company’s per share price at $2.39 changed hands at $0.32 or 15.46% during last session, the market valuation stood at $103.29M. KYTX’s last price was a discount, traded about -613.81% off its 52-week high of $17.06. The share price had its 52-week low at $1.78, which suggests the last value was 25.52% up since then.
Analysts gave the Kyverna Therapeutics Inc (KYTX) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended KYTX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight.
Kyverna Therapeutics Inc (NASDAQ:KYTX) trade information
Instantly KYTX was in green as seen at the end of in last trading. With action 3.02%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -36.10%, with the 5-day performance at 3.02% in the green. However, in the 30-day time frame, Kyverna Therapeutics Inc (NASDAQ:KYTX) is 20.10% up.
The 2025 estimates are for Kyverna Therapeutics Inc earnings to decrease by -11.70%, but the outlook for the next 5-year period is at -2.34% per year.
KYTX Dividends
Kyverna Therapeutics Inc is expected to release its next quarterly earnings report in June.
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC holds the second largest percentage of outstanding shares, with 7.8106% or 3.37 million shares worth $25.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were JPMorgan Trust II-JPMorgan Small Cap Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 1.0 shares estimated at $2.4 million under it, the former controlled 2.32% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.87% of the shares, roughly 806.42 shares worth around $1.93 million.
